Anti-SCN9A Antibody

Primary Antibody for Pain Pathway Research

This polyclonal antibody from Antibodies.com targets SCN9A, the gene encoding the Nav1.7 voltage-gated sodium channel. Nav1.7 is preferentially expressed in nociceptive (pain-sensing) neurons of the dorsal root ganglia and trigeminal ganglia, and is widely studied in pain signaling research.

Generated in Rabbit and supplied as an unconjugated polyclonal reagent, this antibody is validated for Western blot (WB) and immunohistochemistry (IHC) workflows. It cross-reacts with both Human and Mouse samples, supporting translational studies that span patient-derived tissues and murine disease models.

Researchers investigating inherited pain disorders such as erythromelalgia, paroxysmal extreme pain disorder, and congenital insensitivity to pain rely on SCN9A antibodies to assess channel expression and distribution. Nav1.7 has attracted attention as a therapeutic target for next-generation analgesics, and reliable detection reagents are essential for screening candidate compounds and characterizing tissue expression patterns. Each vial contains 100 µl of antibody, supporting multiple experimental setups.